Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Investing Activities (2021 - 2024)

InMed Pharmaceuticals (INM) has 4 years of Cash from Investing Activities data on record, last reported at -$2.0 in Q1 2024.

  • For Q1 2024, Cash from Investing Activities rose 100.0% year-over-year to -$2.0; the TTM value through Jun 2024 reached -$161806.0, up 81.84%, while the annual FY2024 figure was -$9293.0, 98.6% up from the prior year.
  • Cash from Investing Activities reached -$2.0 in Q1 2024 per INM's latest filing, up from -$33606.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $306011.0 in Q4 2021 and bottomed at -$725457.0 in Q2 2022.
  • Average Cash from Investing Activities over 4 years is -$119257.9, with a median of -$33606.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: crashed 3508.16% in 2023, then surged 100.0% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at $306011.0 in 2021, then crashed by 337.07% to -$725457.0 in 2022, then surged by 95.37% to -$33606.0 in 2023, then surged by 99.99% to -$2.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$2.0 in Q1 2024, -$33606.0 in Q2 2023, and -$128198.0 in Q1 2023.